DoMore Diagnostics

📍 Oslo, Norway🗓 Founded 2021👥 14 employees💰 Last funded Jan 2023
Hospitals and Health Care🌐 domorediagnostics.com
Website LinkedIn
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. The company is based on prominent international research from leading universities and funded by top Norwegian tech investors.
4
Total investors
4
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Norway
3
Germany
1
Investor activity2021–2023 · investors recorded per year
2021220232
Recent (last 2y)Earlier
Frequently asked questions
Who invested in DoMore Diagnostics?
DoMore Diagnostics has 4 investors on record on gritt.io, including 4 early-stage backers.
When did DoMore Diagnostics last raise funding?
The most recent investment in DoMore Diagnostics recorded on gritt.io was in January 2023.
When was DoMore Diagnostics founded?
DoMore Diagnostics was founded in 2021.
What industry is DoMore Diagnostics in?
DoMore Diagnostics operates in Hospitals and Health Care. Find similar Hospitals and Health Care investors on gritt.io.
Where is DoMore Diagnostics based?
DoMore Diagnostics is headquartered in Oslo, Norway.